Icosapent ethyl (VASCEPA®) as treatment for post-acute sequelae of SARS CoV-2 (PASC) vaccine induced injury and infection
Description
CONCLUSION: After review and analysis we conclude that Icosapent Ethyl may have been a determining factor in Long COVID symptom resolution and should be studied further.